SCHEMBL6086606

SCHEMBL6086606

CCN1C(=O)CSC1=C(C#N)C(=O)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.59
▸ KMT2A Q03164 5/20 0.59
▸ MAPT P10636 4/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ ALDH1A1 P00352 5/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.44
▸ HPGD P15428 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ BRCA1 P38398 1/20 0.44
▸ GSK3A P49840 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DHODH Q02127 6/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086601 1.00 MEN1 (0.59) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL6087108 0.83 MEN1 (0.62) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL6087113 0.83 MEN1 (0.62) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL13488663 0.83 MEN1 (0.54) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL3353294 0.83 MEN1 (0.54) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL5174367 0.80 MAPT (0.54) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL5174362 0.80 MAPT (0.54) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL6087214 0.76 MEN1 (0.48) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL3358918 0.75 ALDH1A1 (0.49) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL3905980 0.75 MAPT (0.48) MEN1KMT2AMAPTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors SCHERING AKTIENGESELLSCHAFT 2006-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors PLK4, PLK2, PLK3 MEN1 3800/4885KMT2A 3723/4885MAPT 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback